Search Results - livio+trusolino

2 Results Sort By:
Genetic Alterations Related to Anti-EGFR Therapeutic Response
Unmet Need:Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are monoclonal antibodies, which prevent epidermal growth factor receptor (EGFR) activation. Several studies have identified alterations in KRAS and other genes...
Published: 6/27/2024   |   Inventor(s): Livio Trusolino, Andrea Bertotti, Victor Velculescu, Vilmos Adleff, Eniko Papp
Keywords(s): Biomarker, Cancers, Colorectal Cancer, Disease Indication, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer
A p105-based NF-(kappa) B Super repressor
C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...
Published: 6/27/2024   |   Inventor(s): Li Lin
Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum